ANI Total Assets vs Long Term Debt Analysis

ANIP Stock

USD 61.43 2.34 3.67%

ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Total Assets and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Total Assets vs Long Term Debt

Total Assets vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Total Assets account and Long Term Debt. At this time, the significance of the direction appears to have very strong relationship.

The correlation between ANI Pharmaceuticals' Total Assets and Long Term Debt is 0.87. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Total Assets and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of ANI Pharmaceuticals are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Assets i.e., ANI Pharmaceuticals' Total Assets and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.87

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Assets

Total assets refers to the total amount of ANI Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ANI Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Long Term Debt

Long-term debt is a debt that ANI Pharmaceuticals has held for over one year. Long-term debt appears on ANI Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on ANI Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.As of 05/18/2024, Selling General Administrative is likely to grow to about 157.9 M, while Discontinued Operations is likely to drop slightly above 156 K.

	2021	2022	2023	2024 (projected)
Gross Profit	115.5M	177.6M	245.5M	257.8M
Total Revenue	216.1M	316.4M	486.8M	511.2M

Gross Profit Total Revenue

ANI Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Stockholder Equity	Short Long Term Debt Total	Short Term Debt	Current Deferred Revenue	Non Currrent Assets Other	Non Current Liabilities Total	Net Receivables	Net Tangible Assets
Total Assets		0.95	0.84	1.0	0.9	0.7	0.16	0.94	0.6	0.95	0.6	-0.48	0.93	0.53	1.0	0.96	0.95	-0.48	0.98	0.97	-0.19	0.09	0.52	0.92	0.97	0.09
Other Current Liab	0.95		0.87	0.95	0.88	0.61	0.06	0.97	0.58	0.87	0.58	-0.38	0.84	0.61	0.94	0.95	0.93	-0.38	0.94	0.89	-0.24	-0.09	0.44	0.85	0.96	0.14
Total Current Liabilities	0.84	0.87		0.83	0.86	0.65	0.16	0.81	0.43	0.82	0.43	-0.37	0.77	0.48	0.85	0.85	0.77	-0.37	0.79	0.82	-0.06	-0.17	0.57	0.65	0.83	-0.09
Total Stockholder Equity	1.0	0.95	0.83		0.88	0.64	0.15	0.94	0.66	0.92	0.66	-0.48	0.93	0.56	0.98	0.95	0.96	-0.48	0.99	0.96	-0.15	0.12	0.56	0.92	0.95	0.15
Property Plant And Equipment Net	0.9	0.88	0.86	0.88		0.83	0.26	0.83	0.32	0.95	0.32	-0.48	0.79	0.43	0.92	0.94	0.76	-0.48	0.85	0.91	-0.26	-0.22	0.33	0.81	0.9	-0.09
Net Debt	0.7	0.61	0.65	0.64	0.83		0.32	0.56	-0.13	0.88	-0.13	-0.46	0.61	0.16	0.74	0.74	0.44	-0.46	0.62	0.74	-0.26	-0.11	0.21	0.66	0.75	-0.46
Retained Earnings	0.16	0.06	0.16	0.15	0.26	0.32		-0.06	-0.04	0.27	-0.04	-0.89	0.3	-0.01	0.17	0.08	0.04	-0.89	0.18	0.26	0.4	0.33	0.4	0.02	0.05	-0.18
Accounts Payable	0.94	0.97	0.81	0.94	0.83	0.56	-0.06		0.62	0.83	0.62	-0.31	0.8	0.65	0.93	0.96	0.94	-0.31	0.93	0.89	-0.38	-0.12	0.38	0.89	0.96	0.22
Cash	0.6	0.58	0.43	0.66	0.32	-0.13	-0.04	0.62		0.34	1.0	-0.19	0.63	0.46	0.55	0.47	0.81	-0.19	0.65	0.52	0.1	0.35	0.54	0.52	0.47	0.61
Non Current Assets Total	0.95	0.87	0.82	0.92	0.95	0.88	0.27	0.83	0.34		0.34	-0.52	0.86	0.39	0.96	0.93	0.79	-0.52	0.9	0.95	-0.19	0.03	0.45	0.87	0.93	-0.16
Cash And Short Term Investments	0.6	0.58	0.43	0.66	0.32	-0.13	-0.04	0.62	1.0	0.34		-0.19	0.63	0.46	0.55	0.47	0.81	-0.19	0.65	0.52	0.1	0.35	0.54	0.52	0.47	0.61
Common Stock Total Equity	-0.48	-0.38	-0.37	-0.48	-0.48	-0.46	-0.89	-0.31	-0.19	-0.52	-0.19		-0.57	-0.33	-0.48	-0.41	-0.39	1.0	-0.53	-0.58	-0.21	-0.33	-0.54	-0.39	-0.4	0.01
Common Stock Shares Outstanding	0.93	0.84	0.77	0.93	0.79	0.61	0.3	0.8	0.63	0.86	0.63	-0.57		0.46	0.91	0.82	0.89	-0.57	0.93	0.92	0.09	0.35	0.68	0.84	0.84	0.11
Other Current Assets	0.53	0.61	0.48	0.56	0.43	0.16	-0.01	0.65	0.46	0.39	0.46	-0.33	0.46		0.5	0.56	0.6	-0.33	0.62	0.61	-0.38	-0.16	0.45	0.59	0.55	0.14
Total Liab	1.0	0.94	0.85	0.98	0.92	0.74	0.17	0.93	0.55	0.96	0.55	-0.48	0.91	0.5		0.97	0.92	-0.48	0.97	0.97	-0.22	0.06	0.49	0.92	0.97	0.05
Property Plant And Equipment Gross	0.96	0.95	0.85	0.95	0.94	0.74	0.08	0.96	0.47	0.93	0.47	-0.41	0.82	0.56	0.97		0.89	-0.41	0.94	0.94	-0.34	-0.16	0.36	0.91	0.98	0.08
Total Current Assets	0.95	0.93	0.77	0.96	0.76	0.44	0.04	0.94	0.81	0.79	0.81	-0.39	0.89	0.6	0.92	0.89		-0.39	0.96	0.89	-0.17	0.14	0.54	0.87	0.9	0.34
Common Stock	-0.48	-0.38	-0.37	-0.48	-0.48	-0.46	-0.89	-0.31	-0.19	-0.52	-0.19	1.0	-0.57	-0.33	-0.48	-0.41	-0.39		-0.53	-0.58	-0.21	-0.33	-0.54	-0.39	-0.4	0.01
Other Stockholder Equity	0.98	0.94	0.79	0.99	0.85	0.62	0.18	0.93	0.65	0.9	0.65	-0.53	0.93	0.62	0.97	0.94	0.96	-0.53		0.97	-0.17	0.14	0.57	0.93	0.95	0.18
Short Long Term Debt Total	0.97	0.89	0.82	0.96	0.91	0.74	0.26	0.89	0.52	0.95	0.52	-0.58	0.92	0.61	0.97	0.94	0.89	-0.58	0.97		-0.2	0.09	0.58	0.92	0.94	0.01
Short Term Debt	-0.19	-0.24	-0.06	-0.15	-0.26	-0.26	0.4	-0.38	0.1	-0.19	0.1	-0.21	0.09	-0.38	-0.22	-0.34	-0.17	-0.21	-0.17	-0.2		0.57	0.44	-0.38	-0.35	0.12
Current Deferred Revenue	0.09	-0.09	-0.17	0.12	-0.22	-0.11	0.33	-0.12	0.35	0.03	0.35	-0.33	0.35	-0.16	0.06	-0.16	0.14	-0.33	0.14	0.09	0.57		0.55	0.07	-0.07	0.08
Non Currrent Assets Other	0.52	0.44	0.57	0.56	0.33	0.21	0.4	0.38	0.54	0.45	0.54	-0.54	0.68	0.45	0.49	0.36	0.54	-0.54	0.57	0.58	0.44	0.55		0.37	0.38	-0.07
Non Current Liabilities Total	0.92	0.85	0.65	0.92	0.81	0.66	0.02	0.89	0.52	0.87	0.52	-0.39	0.84	0.59	0.92	0.91	0.87	-0.39	0.93	0.92	-0.38	0.07	0.37		0.92	0.1
Net Receivables	0.97	0.96	0.83	0.95	0.9	0.75	0.05	0.96	0.47	0.93	0.47	-0.4	0.84	0.55	0.97	0.98	0.9	-0.4	0.95	0.94	-0.35	-0.07	0.38	0.92		0.06
Net Tangible Assets	0.09	0.14	-0.09	0.15	-0.09	-0.46	-0.18	0.22	0.61	-0.16	0.61	0.01	0.11	0.14	0.05	0.08	0.34	0.01	0.18	0.01	0.12	0.08	-0.07	0.1	0.06

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Liab	36.7M	54.0M	63.6M	69.3M	99.8M	104.8M
Total Current Liabilities	61.7M	78.6M	87.5M	99.4M	145.5M	152.8M
Total Stockholder Equity	212.8M	195.7M	358.7M	338.5M	432.7M	454.4M
Property Plant And Equipment Net	40.6M	41.3M	52.7M	43.2M	44.6M	46.8M
Net Debt	123.4M	177.8M	187.1M	238.3M	94.2M	98.9M
Retained Earnings	17.6M	(5.0M)	(47.8M)	(97.3M)	(80.1M)	(84.1M)
Accounts Payable	14.6M	11.3M	23.0M	29.3M	36.7M	38.5M
Cash	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Non Current Assets Total	269.1M	290.9M	449.8M	415.8M	384.8M	404.0M
Cash And Short Term Investments	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Common Stock Shares Outstanding	12.0M	12.0M	12.6M	16.3M	18.2M	19.1M
Liabilities And Stockholders Equity	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Assets	5.1M	5.9M	11.3M	8.4M	25.2M	26.5M
Total Liab	244.0M	265.5M	412.9M	421.5M	471.7M	495.3M
Property Plant And Equipment Gross	40.6M	41.3M	75.6M	76.0M	77.5M	81.4M
Total Current Assets	187.7M	170.3M	321.8M	344.3M	519.6M	545.6M
Other Stockholder Equity	200.1M	212.1M	384.7M	398.8M	479.2M	503.1M
Accumulated Other Comprehensive Income	(4.9M)	(11.4M)	(3.1M)	12.2M	8.9M	9.3M
Short Long Term Debt Total	185.7M	185.7M	287.4M	286.5M	315.3M	331.1M
Short Term Debt	115.7M	9.9M	13.2M	850K	977.5K	928.6K
Current Deferred Revenue	451K	80K	87K	8.2M	9.4M	9.9M
Non Currrent Assets Other	1.2M	802K	2.2M	2.6M	6.1M	6.4M
Non Current Liabilities Total	182.3M	186.9M	325.3M	322.1M	326.2M	342.5M
Net Receivables	72.1M	95.8M	128.5M	165.4M	162.1M	170.2M
Net Tangible Assets	28.8M	3.6M	36.7M	58.7M	52.8M	55.5M
Other Assets	44.6M	57.5M	75.1M	92.7M	106.6M	112.0M
Long Term Debt	175.8M	172.4M	286.5M	285.7M	284.8M	149.2M
Retained Earnings Total Equity	17.6M	(5.0M)	(47.8M)	(97.3M)	(111.9M)	(117.5M)
Inventory	48.2M	60.8M	81.7M	105.4M	111.2M	116.8M
Deferred Long Term Liab	1.5M	800K	500K	600K	690K	458.1K
Intangible Assets	180.4M	188.5M	294.1M	251.6M	209.0M	156.5M
Property Plant Equipment	40.6M	41.3M	52.7M	43.2M	49.7M	52.2M
Capital Surpluse	200.8M	214.4M	387.8M	403.9M	464.5M	237.5M
Other Liab	7K	201K	31.0M	35.1M	40.3M	42.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether ANI Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ANI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ani Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Ani Pharmaceuticals Stock:

How To Invest In ANI

Details

Is ANI Stock a good investment?

Details

What is ANI Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for ANI Stock analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

13.824

Earnings Share

1.61

Revenue Per Share

27.705

Quarterly Revenue Growth

0.287

Return On Assets

0.0391

The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Total Assets vs Long Term Debt Analysis

Total Assets vs Long Term Debt

Total Assets vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Assets

Long Term Debt

ANI Pharmaceuticals fundamental ratios Correlations

ANI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ANI Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for ANI Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.98	Total Assets

Common Stock	- 0.89	Retained Earnings
Common Stock Total Equity	- 0.89	Retained Earnings
Short Long Term Debt Total	- 0.58	Common Stock
Short Long Term Debt Total	- 0.58	Common Stock Total Equity
Common Stock	- 0.57	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.57	Common Stock Total Equity